JP2007509110A5 - - Google Patents

Download PDF

Info

Publication number
JP2007509110A5
JP2007509110A5 JP2006536092A JP2006536092A JP2007509110A5 JP 2007509110 A5 JP2007509110 A5 JP 2007509110A5 JP 2006536092 A JP2006536092 A JP 2006536092A JP 2006536092 A JP2006536092 A JP 2006536092A JP 2007509110 A5 JP2007509110 A5 JP 2007509110A5
Authority
JP
Japan
Prior art keywords
compound
formula
treatment
antagonist
prevention
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2006536092A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007509110A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2004/052618 external-priority patent/WO2005039566A1/en
Publication of JP2007509110A publication Critical patent/JP2007509110A/ja
Publication of JP2007509110A5 publication Critical patent/JP2007509110A5/ja
Withdrawn legal-status Critical Current

Links

JP2006536092A 2003-10-24 2004-10-22 Ｃｂ１拮抗活性を有する４，５−ジヒドロ−１ｈ−ピラゾール誘導体とリパーゼ阻害剤とを含む組み合わせでの肥満症治療 Withdrawn JP2007509110A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP03103961 2003-10-24
PCT/EP2004/052618 WO2005039566A1 (en) 2003-10-24 2004-10-22 Combination treatment of obesity involving 4,5-dihydro-1h-pyrazole derivatives having cb1-antagonistic activity and lipase inhibitors

Publications (2)

Publication Number Publication Date
JP2007509110A JP2007509110A (ja) 2007-04-12
JP2007509110A5 true JP2007509110A5 (https=) 2007-09-06

Family

ID=34486362

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006536092A Withdrawn JP2007509110A (ja) 2003-10-24 2004-10-22 Ｃｂ１拮抗活性を有する４，５−ジヒドロ−１ｈ−ピラゾール誘導体とリパーゼ阻害剤とを含む組み合わせでの肥満症治療

Country Status (13)

Country Link
EP (1) EP1680106B1 (https=)
JP (1) JP2007509110A (https=)
CN (2) CN1997364A (https=)
AR (1) AR046132A1 (https=)
AT (1) ATE438394T1 (https=)
AU (1) AU2004283055A1 (https=)
BR (1) BRPI0415463A (https=)
CA (1) CA2543342A1 (https=)
DE (1) DE602004022445D1 (https=)
MX (1) MXPA06004390A (https=)
RU (1) RU2006117639A (https=)
TW (1) TW200528102A (https=)
WO (1) WO2005039566A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2008002193A (es) * 2005-08-17 2008-03-25 Solvay Pharm Gmbh Metodos para usar compuestos inhibidores del canal de potasio.
CN102731418B (zh) * 2012-07-15 2015-03-11 浙江大学 1-取代-1h-1,2,4-三氮唑-甲酰胺衍生物及其制备和用途
CN113166068B (zh) * 2018-11-20 2024-08-16 上海科技大学 MmpL3抑制剂、组合物及其用途
CN117551046B (zh) * 2023-11-17 2025-10-28 广东药科大学附属第一医院 二氨基脲类hsl抑制剂、制备方法及其用途

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA74367C2 (uk) * 2000-03-23 2005-12-15 Сольве Фармас'Ютікалз Б.В. ПОХІДНІ 4,5-ДИГІДРО-1Н-ПІРАЗОЛУ, ЩО ВИЯВЛЯЮТЬ АНТАГОНІСТИЧНУ АКТИВНІСТЬ ЩОДО СВ<sub>1</sub>, СПОСІБ ЇХ ОДЕРЖАННЯ, ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ ТА СПОСІБ ЇЇ ВИГОТОВЛЕННЯ, СПОСІБ ЛІКУВАННЯ ЗАХВОРЮВАНЬ (ВАРІАНТИ)
SK287592B6 (sk) * 2001-03-22 2011-03-04 Solvay Pharmaceuticals B. V. 4,5-Dihydro-1H-pyrazolové deriváty, ktoré majú CB1-antagonistickú účinnosť, spôsob ich prípravy a použitie
HUP0401567A3 (en) * 2001-09-21 2005-06-28 Solvay Pharm Bv Novel 4,5-dyhydro-1h-pyrazole derivatives having cb1-antagonistic activity, their use and pharmaceutical compositions containing them
HRP20030913A2 (en) * 2001-09-21 2004-06-30 Solvay Pharm Bv 4,5-dihydro-1h-pyrazole derivatives having potent cb1-antagonistic activity
SE0104330D0 (sv) * 2001-12-19 2001-12-19 Astrazeneca Ab Therapeutic agents
GB0202015D0 (en) * 2002-01-29 2002-03-13 Hoffmann La Roche Piperazine Derivatives
AU2003209388A1 (en) * 2002-01-29 2003-09-02 Merck And Co., Inc. Substituted imidazoles as cannabinoid receptor modulators
TW200412942A (en) * 2002-08-06 2004-08-01 Abbott Lab Appetite control method
US20040122033A1 (en) * 2002-12-10 2004-06-24 Nargund Ravi P. Combination therapy for the treatment of obesity
JP2007506654A (ja) * 2003-06-20 2007-03-22 エフ．ホフマン−ラ　ロシュ　アーゲー Ｃｂ１受容体逆作動物質としての２−アミノベンゾチアゾール類
AU2004283903B2 (en) * 2003-10-20 2010-12-02 Solvay Pharmaceuticals B.V. 1H-imidazole derivatives as cannabinoid receptor modulators
WO2005039550A2 (en) * 2003-10-24 2005-05-06 Solvay Pharmaceuticals Gmbh Novel medical uses of compounds showing cb1-antagonistic activity and combination treatment involving said compounds

Similar Documents

Publication Publication Date Title
RU2397168C2 (ru) Производные тиофена в качестве ингибиторов снк 1
WO2007096151A3 (en) Inhibitors of p38-kinase for treatment of pulmonary hypertension
JP2008510770A5 (https=)
JP2014503574A5 (https=)
EP1489077A4 (en) 2- FURANCARA ACID HYDRATES AND PHARMACEUTICAL COMPOSITION CONTAINING THEM
JP2010501478A5 (https=)
NO20072978L (no) Nye betuinderivater, preparat derav og anvendelse derav
WO2006069155A3 (en) Inhibitors of protein arginine methyl transferases
JP2007519649A5 (https=)
EP4467549A3 (en) Intermediates of n-(3-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)phenyl)benzamide derivatives
JP2007508360A5 (https=)
JP2002030084A5 (https=)
JP2010532387A5 (https=)
JP2006508953A5 (https=)
WO2007056219A3 (en) [4-(6-halo-7-substituted-2,4-dioxo-1,4-dihydro-2h-quinazolin-3-yl)-phenyl]-5-chloro-thiophen-2-yl-sulfonylureas and forms and methods related thereto
WO2009013348A3 (en) Pyrimidine derivatives useful for the treatment of inflammatory or allergic conditions
DE602004008959D1 (de) Benzoäbüä1,4üdioxepinderivate
JP2016511262A5 (https=)
CN115315423A (zh) 取代芳基类化合物
JP2009541387A5 (https=)
IL313466A (en) Inhibiting creb binding protein (cbp)
WO2008000421A3 (en) Thiazolyl urea derivatives as phosphatidylinositol 3-kinase inhibitors
WO2008137809A3 (en) [4-(6-fluoro-7-methylamino-2,4-dioxo-1,4-dihydro-2h-quinazolin-3-yl)-phenyl] -5-chloro-thiophen-2-yl-sulfonylurea salts, in different crystalline forms, pharmaceutical compositions thereof
JP2009501745A5 (https=)
JP2007509110A5 (https=)